View Author
cancer patient breast plasminogen tumor level activator expression protein breast cancer inhibitor urokinase-type plasminogen activator prognostic pai ‑1 study upar-del tissue survival receptor 4/5 carcinoma biomarker analysis urokinase-type urokinase therapy rab 31 factor upar-del 4/5 value system metastasi status plasminogen activator inhibitor breast cancer patients upar-wt urokinase plasminogen activator pai ‑1 levels cell carcinoma trial sample 160 kda form prognosis cancer patients cancer res kinase association disease outcome tumour upa levels signi grade signi ficantly antibody 78 kda form pai ‑1 expression utility marker treatment . cancer table stage invasion cancer biomarkers breast cancer res prognostic relevance progression phase relevance colorectal anticancer res . oncol cancer biomarker oncol schmitt 160 kda protein pkcd mrna tumor tissue review
3 Most Recent Publications
|
Clinical utility of level-of-evidence-1 disease forecast cancer biomarkers uPA and its inhibitor PAI-1
(Article)
Schmitt, M. Mengele, K. Napieralski, R. Magdolen, V. Reuning, U. Gkazepis, A. Sweep, F.C. Brünner, N. Foekens, J.A. Harbeck, N. |
2010-11-01
|
|
Protein kinase Cδ expression in breast cancer as measured by real-time PCR, western blotting and ELISA
(Article)
McKiernan, E. O'Brien, K. Sweep, F.C. Duffy, M.J. Grebenchtchikov, N. Geurts-Moespot, A. Sieuwerts, A.M. Martens, J.W.M. Magdolen, V. Evoy, D. McDermott, E. Crown, J. |
2008-11-04
|
|
Urokinase receptor splice variant uPAR-del4/5-associated gene expression in breast cancer: Identification of rab31 as an independent prognostic factor
(Article)
Kotzsch, M. Sieuwerts, A.M. Magdolen, V. Foekens, J.A. Grosser, M. Meye, A. Fuessel, S. Meijer van Gelder, M.E. Smid, M. Schmitt, M. Baretton, G. Luther, T. |
2008-09-01
|
